Drug-induced liver injury: A summary of recent advances

Jonathan Stine, James H. Lewis

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

Introduction: The knowledge base of drug-induced liver injury (DILI) continues to grow each year as additional drugs are identified as hepatotoxins. There is still a need to improve our ability to predict and diagnose DILI in the preclinical and post-approval settings. Areas covered: This article presents the new and updated DILI registries for 2010, including the latest information on the causes and outcomes of non-acetaminophen DILI cases in the US Acute Liver Failure Study Group database. As DILI is still largely a diagnosis of exclusion, it is appropriate that causality assessment instruments are again the subject of considerable discussion. Expert opinion: DILI research remains extremely active including studies aimed at being better able to identify causative agents, utilize potential biomarkers, predict who is at greatest risk of injury and manage outcomes. With respect to identifying DILI risk factors at the genetic level, the field is rapidly approaching the day where 'personalized medicine' (based on pharmacogenomics) will become a reality. A large single-center series from India reminds us that geography can influence the drugs responsible for liver injury; however, Hy's law remains universal. As our DILI knowledge continues to grow, it remains essential to keep abreast of the important changes reported each year.

Original languageEnglish (US)
Pages (from-to)875-890
Number of pages16
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume7
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Chemical and Drug Induced Liver Injury
Liver
Pharmaceutical Preparations
Precision Medicine
Geography
Knowledge Bases
Acute Liver Failure
Pharmacogenetics
Wounds and Injuries
Expert Testimony
Causality
Registries
Biomarkers
India
Medicine
Databases

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

@article{71a37e1c167b4ec99904dd0947539c8c,
title = "Drug-induced liver injury: A summary of recent advances",
abstract = "Introduction: The knowledge base of drug-induced liver injury (DILI) continues to grow each year as additional drugs are identified as hepatotoxins. There is still a need to improve our ability to predict and diagnose DILI in the preclinical and post-approval settings. Areas covered: This article presents the new and updated DILI registries for 2010, including the latest information on the causes and outcomes of non-acetaminophen DILI cases in the US Acute Liver Failure Study Group database. As DILI is still largely a diagnosis of exclusion, it is appropriate that causality assessment instruments are again the subject of considerable discussion. Expert opinion: DILI research remains extremely active including studies aimed at being better able to identify causative agents, utilize potential biomarkers, predict who is at greatest risk of injury and manage outcomes. With respect to identifying DILI risk factors at the genetic level, the field is rapidly approaching the day where 'personalized medicine' (based on pharmacogenomics) will become a reality. A large single-center series from India reminds us that geography can influence the drugs responsible for liver injury; however, Hy's law remains universal. As our DILI knowledge continues to grow, it remains essential to keep abreast of the important changes reported each year.",
author = "Jonathan Stine and Lewis, {James H.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1517/17425255.2011.577415",
language = "English (US)",
volume = "7",
pages = "875--890",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "7",

}

Drug-induced liver injury : A summary of recent advances. / Stine, Jonathan; Lewis, James H.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, No. 7, 01.07.2011, p. 875-890.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Drug-induced liver injury

T2 - A summary of recent advances

AU - Stine, Jonathan

AU - Lewis, James H.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Introduction: The knowledge base of drug-induced liver injury (DILI) continues to grow each year as additional drugs are identified as hepatotoxins. There is still a need to improve our ability to predict and diagnose DILI in the preclinical and post-approval settings. Areas covered: This article presents the new and updated DILI registries for 2010, including the latest information on the causes and outcomes of non-acetaminophen DILI cases in the US Acute Liver Failure Study Group database. As DILI is still largely a diagnosis of exclusion, it is appropriate that causality assessment instruments are again the subject of considerable discussion. Expert opinion: DILI research remains extremely active including studies aimed at being better able to identify causative agents, utilize potential biomarkers, predict who is at greatest risk of injury and manage outcomes. With respect to identifying DILI risk factors at the genetic level, the field is rapidly approaching the day where 'personalized medicine' (based on pharmacogenomics) will become a reality. A large single-center series from India reminds us that geography can influence the drugs responsible for liver injury; however, Hy's law remains universal. As our DILI knowledge continues to grow, it remains essential to keep abreast of the important changes reported each year.

AB - Introduction: The knowledge base of drug-induced liver injury (DILI) continues to grow each year as additional drugs are identified as hepatotoxins. There is still a need to improve our ability to predict and diagnose DILI in the preclinical and post-approval settings. Areas covered: This article presents the new and updated DILI registries for 2010, including the latest information on the causes and outcomes of non-acetaminophen DILI cases in the US Acute Liver Failure Study Group database. As DILI is still largely a diagnosis of exclusion, it is appropriate that causality assessment instruments are again the subject of considerable discussion. Expert opinion: DILI research remains extremely active including studies aimed at being better able to identify causative agents, utilize potential biomarkers, predict who is at greatest risk of injury and manage outcomes. With respect to identifying DILI risk factors at the genetic level, the field is rapidly approaching the day where 'personalized medicine' (based on pharmacogenomics) will become a reality. A large single-center series from India reminds us that geography can influence the drugs responsible for liver injury; however, Hy's law remains universal. As our DILI knowledge continues to grow, it remains essential to keep abreast of the important changes reported each year.

UR - http://www.scopus.com/inward/record.url?scp=79959213923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959213923&partnerID=8YFLogxK

U2 - 10.1517/17425255.2011.577415

DO - 10.1517/17425255.2011.577415

M3 - Review article

C2 - 21510822

AN - SCOPUS:79959213923

VL - 7

SP - 875

EP - 890

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 7

ER -